NCT05950334
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05950334
Title FT522 With Rituximab in Relapsed/Refractory B-Cell Lymphoma (FT522-101)
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Fate Therapeutics
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
Advent Health Orlando Florida 32803 United States Details
Karmanos Cancer Center Detroit Michigan 48201 United States Details
University of Minnesota Masonic Cancer Center Minneapolis Minnesota 55455 United States Details
University of Nebraska Medical Center Omaha Nebraska 68198 United States Details
OU Health Stephenson Cancer Center Oklahoma City Oklahoma 73104 United States Details
Tennessee Oncology Nashville Tennessee 37203 United States Details
Baylor Houston Methodist Hospital Houston Texas 77030 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field